AMP945 Improves Survival in Pacnreatic Cancer Model
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- App 4E - Preliminary Final Report YE 31 March 2021
- Proposed issue of Securities - ATX
- Amplia Announces $3.8m Share Placement
- Preclinical Data Support Developmnt AMP945 Pancreatic Cancer
- Quarterly Report and Shareholder Update
Later from Amplia Therapeutics
- Amplia and Garvan Enter Into Collaboration Agreement
- Results from Successful Phase 1 Clinical Trial of AMP945
- Quarterly Activities and Cashflow Reports and Presentation
- AGM - Chief Executive Officers Presentatioin
- Phase 2 Trial in First-Line Pancreatic Cancer Patients
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics